Optimizing the Procedure to Manufacture Clinical-Grade NK Cells for Adoptive Immunotherapy.
CliniMACS Prodigy
NK cell activation and expansion
NK cell immunotherapy
NKAE cells
clinical-grade manufacturing
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Feb 2021
02 Feb 2021
Historique:
received:
02
12
2020
revised:
14
01
2021
accepted:
26
01
2021
entrez:
5
2
2021
pubmed:
6
2
2021
medline:
6
2
2021
Statut:
epublish
Résumé
Natural killer (NK) cells represent promising tools for cancer immunotherapy. We report the optimization of an NK cell activation-expansion process and its validation on clinical-scale. RPMI-1640, stem cell growth medium (SCGM), NK MACS and TexMACS were used as culture mediums. Activated and expanded NK cells (NKAE) were obtained by coculturing total peripheral blood mononuclear cells (PBMC) or CD45RA NK MACS and TexMACs achieved the highest NK cell purity and lowest T cell contamination. Obtaining NKAE cells from CD45RA GMP-grade NK cells for clinical use can be obtained by using different starting cells and aAPC.
Identifiants
pubmed: 33540698
pii: cancers13030577
doi: 10.3390/cancers13030577
pmc: PMC7867223
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : CRIS FOUNDATION TO BEAT CANCER
ID : NK Cell team Grant
Références
Cytotherapy. 2015 May;17(5):621-32
pubmed: 25881519
J Immunother. 2015 Jan;38(1):24-36
pubmed: 25415285
J Immunother. 2010 Nov-Dec;33(9):945-55
pubmed: 20948442
Bone Marrow Transplant. 2020 May;55(5):929-938
pubmed: 31740766
Blood Cells Mol Dis. 2004 Nov-Dec;33(3):261-6
pubmed: 15528141
Cancer Immunol Immunother. 2010 Dec;59(12):1781-9
pubmed: 20703455
Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10961-6
pubmed: 20534450
Hum Gene Ther. 2017 Oct;28(10):897-913
pubmed: 28810809
Korean J Lab Med. 2009 Apr;29(2):89-96
pubmed: 19411773
Cytotherapy. 2015 Nov;17(11):1594-603
pubmed: 26341478
Blood. 2018 Jun 21;131(25):2863-2866
pubmed: 29728400
Transfus Med Hemother. 2019 Feb;46(1):4-13
pubmed: 31244577
Biol Blood Marrow Transplant. 2018 Nov;24(11):2316-2323
pubmed: 30031939
Tissue Antigens. 2010 Dec;76(6):467-75
pubmed: 20670353
Cytotherapy. 2015 Nov;17(11):1582-93
pubmed: 26432560
Clin Cancer Res. 2017 Oct 1;23(19):5824-5835
pubmed: 28659311
PLoS One. 2012;7(1):e30264
pubmed: 22279576
Clin Cancer Res. 2010 Aug 1;16(15):3901-9
pubmed: 20542985
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Bone Marrow Transplant. 2015 Jul;50(7):968-77
pubmed: 25665048
Front Immunol. 2017 Jun 12;8:676
pubmed: 28659917
Clin Exp Immunol. 2013 Apr;172(1):104-12
pubmed: 23480190
Front Immunol. 2017 Apr 26;8:458
pubmed: 28491060
Nat Rev Drug Discov. 2020 Mar;19(3):200-218
pubmed: 31907401
Nat Immunol. 2008 May;9(5):486-94
pubmed: 18425105
Transfusion. 2018 Jun;58(6):1340-1347
pubmed: 29542132
Sci Rep. 2017 Sep 11;7(1):11075
pubmed: 28894091
Stem Cell Res. 2017 Mar;19:148-155
pubmed: 28171825
Bone Marrow Transplant. 2015 Jul;50(7):886-91
pubmed: 25665044
Cytotherapy. 2016 Jan;18(1):80-90
pubmed: 26549384
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Bone Marrow Transplant. 2018 Mar;53(3):264-273
pubmed: 29269793
Hum Gene Ther Methods. 2019 Jun;30(3):102-120
pubmed: 30997855
Front Oncol. 2013 May 17;3:118
pubmed: 23730623
Bone Marrow Transplant. 2013 Mar;48(3):433-8
pubmed: 22941380
Immunotherapy. 2009 Sep;1(5):753-64
pubmed: 20636021
Front Immunol. 2019 Apr 24;10:879
pubmed: 31105701
Cancer Res. 2009 May 1;69(9):4010-7
pubmed: 19383914
Cancer Lett. 2018 May 28;422:107-117
pubmed: 29477379
Bone Marrow Transplant. 2012 Jan;47(1):73-81
pubmed: 21358682
Oncoimmunology. 2016 Nov 22;5(12):e1250051
pubmed: 28123890
Cancer Res. 2001 Feb 1;61(3):884-8
pubmed: 11221875
Blood. 2005 Apr 15;105(8):3051-7
pubmed: 15632206
Blood. 2011 Sep 22;118(12):3273-9
pubmed: 21791425
Cancer Immunol Immunother. 2010 Nov;59(11):1739-44
pubmed: 20680271
Immunotherapy. 2011 Dec;3(12):1445-59
pubmed: 22091681